The CELEBRATE trial testing the novel injectable glycoprotein IIb/IIIa inhibitor zalunfiban ( Disaggpro; CeleCor Therapeutics) before hospital admission in STEMI patients has met its primary safety and efficacy endpoints in a phase III study, accordi... [1129 chars].. reed more
